However, it is possible to affirm that no effective MS treatments do exist until now, and a major knowledge of the mechanisms and pathways involved in BDNF dysfunction is essential to develop suitable strategies for the MS pathological scenario, as well as to suggest BDNF dysfunction as potential MS biomarker useful in early diagnosis and prognosis. The gene discussed is BDNF; the disease is myeloid sarcoma.